Domestic PD-1 and Small Molecule Strategies: Finish Edg Iii

original title: domestic PD-1 and small molecular strategy: finished ib on the third issue
this article for a few of the varieties of strategy, welcome to add1
Take The Kardashians as an example:recently, their PD-1, Geno mono-resistance (GB226) and Hutchison Whampoa Pharmaceuticals' furanitinib, anti-angiogenic VEGFR target inhibitors, have been used in collaboration with therapiesis expected to conduct clinical Phase Ib patient recruitment in China by the end of 2018 to assess the safety of Genomonoanda (GB226) and furanthanib in selected tumor strains and to determine the dose of the drug;2
Beda and Junshi:December 17, 2018, the first Domestic PD-1, Trepri mono-anti-injection (commodity name: Tuyi) was approved for listingUsed to treat local progression or metastatic melanoma after previous standard treatment failuresClinical trial results of this product showed that the objective remission rate of treating patients with non-reprecision or metastatic melanoma who had previously received systemic treatment was 17.3%, the disease control rate was 57.5%, and the one-year survival rate was 69.3%previously, on July 19, 2018,Beida Pharmaceuticalsannouncement that Kananji received a Notice of Acceptance of Drug Registration Applications issued by the National Drug Administration (NMPA), Vorolanib (CM082) and Shanghai Junsiter Ripley (JS001) to jointly apply for clinical trials of drugs for previously untreated local advances or metastatic mucosal melanoma have been accepted by NMPACM082 is a multi-target receptor tyrosine kinase (RTKs) inhibitor for VEGFR and PDGFR targetsthe author predicts that Beida and Junshi will also adopt the strategy of finishing the Ib IIImore information, see the drug melt data article: "Heavy medicine" domestic PD-1 and small molecule synth joint process at a glance
3 single drug PD-1 and other advantages are not obvious, in this situation, Cinda bio: the introduction of PEMIGatinib (FGFR1/2/3 inhibitors), istinib (JAK1 inhibitor) and parsisaclib (PI3K inhibitor) with its own large-color tumor pipeline Parsaclisib can be combined with the company's CD20 biosimilars, corresponding to NHL (non-Hodgkin's lymphoma ); Pemigatinib can be combined with the company's PD-1 for UC (urinary skin cancer)/bile duct albinoma; Itacitinib can be combined with the company's avastin biosimilars and PD-1, corresponding to NSCLC (non-small cell lung cancer) 4 clinical progress, 38 PD-1/PD-L1 in the clinical 1 According to the drug melt data, Pharnex Datamonitor monitoring shows that: 13 PD-1/PD-L1 in a three-stage or NDA state These include two imported O/K drugs and one of Junshi's PD-1 2 It is expected that the domestic IBI308 will also be approved during the year, SHR-1210, BGB-A317 will be approved for listing next year Note: As of December 18, 2018, data on drug melting more relevant pharmaceutical product information, to join the drug ring